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Abstract
The scientific literature contains evidence suggesting that women who have been treated for breast cancer may, as a result of their
diagnosis, increase their phyto-oestrogen (PE) intake. In the present paper, we describe the creation of a dietary analysis database
(based on Dietplan6) for the determination of dietary intakes of specific PE (daidzein, genistein, glycitein, formononetin, biochanin A,
coumestrol, matairesinol and secoisolariciresinol), in a group of women previously diagnosed and treated for postmenopausal breast
cancer. The design of the database, data evaluation criteria, literature data entry for 551 foods and primary analysis by LC–MS/MS of
an additional thirty-four foods for which there were no published data are described. The dietary intake of 316 women previously treated
for postmenopausal breast cancer informed the identification of potential food and beverage sources of PE and the bespoke dietary
analysis database was created to, ultimately, quantify their PE intake. In order that PE exposure could be comprehensively described,
fifty-four of the 316 subjects completed a 24 h urine collection, and their urinary excretion results allowed for the description of exposure
to include those identified as ‘equol producers’.
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Phyto-oestrogens (PE) are bioactive plant constituents capable
of inducing a wide range of oestrogenic effects in humans(1).
They have been reported to possess antioxidant activities,
anti-inflammatory properties, vasodilatory effects and may
help in the alleviation of menopausal symptoms(2). There is
some evidence of their effect on reducing the age-related
decline in bone density(3), and in the reduction of the inci-
dence of CVD and hormone-dependent cancers. Individual
studies continue to report reduced cancer risk with increasing
PE intake(4), while the conclusions from meta-analysis are
more restrained, suggesting both soya and lignan intake may
be associated with small reductions in breast cancer
risk(5–9). Consequently, the question of whether or not PE
are beneficial or harmful to human health remains unresolved.
The answer is likely to be complex and may depend on age at
exposure to PE, health status and even the presence or
absence of specific gut microflora. Clarity on this issue is
needed because global consumption of PE is rapidly increas-
ing(10). Evidence indicates that women who have been treated
for breast cancer may, as a result of their diagnosis, increase
their PE intake, perhaps as an alternative to conventional hor-
mone replacement therapy, or because of a belief that PE may
help them avoid a recurrence of the disease(11–13). At this
stage, there is no recommended intake for PE and there are
concerns about the safety of a high PE intake(14), especially
in subgroups of the population such as breast cancer patients.
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In order to assess the impact of PE intake on health, a
thorough understanding of the PE content of a wide range
of foods present in the diet is required. In practice, assessing
the impact can be achieved either by replacement of diet(15),
dietary supplementation(16), direct analysis of duplicate
diets(17), or indirectly through total diet studies(18), FFQ(19)
and food compositional databases(20). Compositional data-
bases require the prior analysis of all items of food consumed
by a given population and often must contain many thousands
of entries(21). Further, Internet-based resources offer a wider
availability to food composition data(22). Once a database is
fully populated and its use validated against a direct analysis
method, then indirect dietary intake estimation, by FFQ, is
relatively inexpensive.
Several databases have been constructed containing the PE
content of foods and beverages. Some have focused on selected
isoflavones(23), while others have included both isoflavones and
lignans(22,24–27). An inventory of PE databases has been pub-
lished, with the guidance on the selection of best-suited data-
bases and recommendations on their suitability(17). Estimation
of PE intake in Western countries has historically been biased
towards underestimations by the inadequacy of coverage of
key local foods and the increasing prevalence of soya ingredi-
ents in the production of frequently consumed processed
foods which are not generally recognised as PE sources.
Serum PE measurement is well known to be a poor index of
long-term PE intake, while 24 h urinary PE excretion estimates
perform much better and are considered to be more reliable(28).
Method
Recruitment and experimental design
Between January 2000 and November 2005, a dietary change
feasibility study, The Women’s Intervention Nutrition Study
(UK) (WINS (UK) – stage 1), recruited postmenopausal
women previously treated for breast cancer. A set of two hun-
dred and sixty-one 4 d food and drink diaries and sixteen 7 d
weighed intake diaries were collected as part of the preliminary
screening for eligibility for WINS (UK) – stage 1, and it was
noted that subjects reported some soya-rich products in their
diets. These diaries were available for re-analysis(29). All
women who had completed the WINS (UK) – stage 1 baseline
screening diaries were contacted to ask for their consent to re-
analyse their diaries in order to describe PE consumption pat-
terns for this newly funded study. To allow 24 h urinalysis of
PE urinary metabolites and comparisons with dietary intake
estimations, fifty-five additional subjects were recruited to the
PE study using the original WINS (UK) – stage 1 criteria, and
summary data on screening, recruitment and participation for
the PE study were compiled according to the Consolidated Stan-
dards of Reporting Trials guidance(30). The criteria for eligibility
were as follows: postmenopausal and aged 48–78 years at diag-
nosis with breast cancer, histologically confirmed stage I, II or
IIIa breast cancer, not participating in any conflicting studies,
not following a special therapeutic diet, no past history of
eating disorders, able to speak, read and write English and
being geographically accessible for follow-up.
24 h urine collection and urinalysis
Of the fifty-five eligible subjects, fifty-four complied with the
urine collection methodology which used 3-litre containers
with ascorbic acid as a preservative and PABAcheck tablets
( para-aminobenzoic acid (PABA); Laboratories for Applied
Biology Limited), according to a standard community-based
24 h urine collection protocol. The subjects took one 80 mg
tablet with each of the three main meals eaten on the day of
urine collection. PABA in urine was measured colorimetrically
by absorbance at 540 nm, after alkaline hydrolysis and a diazo
coupling reaction with nitrous acid(31) to confirm the comple-
teness of the urine collection. A quality-control sample was
run in triplicate within each analytical run. The completeness
of the urine collection was assessed in terms of the percentage
excretion of the total dose (240 mg) of PABA.
Database
A bespoke version of Dietplan6 (version 6.20c7, 2006; Forest-
field Software Limited UK) database was created from both
published and primary analysis sources to estimate PE
intake. Careful consideration was given to data quality, includ-
ing its origin and applicability to human dietary intake. A data
quality criteria and scoring system for published values in
peer-reviewed literature was compiled and used to determine
Table 1. Data quality criteria and scoring system for published literature
Criteria Score
(1) Data published in peer-reviewed articles or data of
equivalent quality
1
(2) Use of analytical reagents or better 1
(3) Use of appropriate high-quality internal standards
from recognised sources
1
(4) Use of isotopically labelled standards 1
(5) Clear description of sampling procedure
(use of at least three samples)
1
(6) Use of appropriate treated glassware (derivatisation)
within the method
1
(7) Clear description of extraction procedure 1
(8) Use of enzymatic or acidic hydrolysis (or measurement
of both glucosides and aglycones)
1
(9) Use of HPLC with positive confirmation of peaks
by other means (e.g. ESI–MS)
1
(10) Use of LC–MS with appropriate identification
of peaks
1
(11) Evidence of baseline chromatographic separation
of analytes
1
(12) Evidence of LOD and LOQ of method 1
(13) Clear details on the recovery of the analyte
(ideally greater than 60 %)
1
(14) Clear details on the calculation of results 1
(15) Clear presentation of results in terms of
expression as aglycone or glucoside
1
(16) Clear presentation of results in terms of dry
weight or wet weight
1
(17) Ability to quantify phyto-oestrogen content as
aglycone equivalents
1
(18) Evidence of the usage of quality-control procedures
during analysis
1
(19) Clear information on inter- and intra-assay variation 1
(20) Results in line with those derived by other analysts 1
ESI, electrospray ionisation; LOD, limit of detection; LOQ, limit of quantification.
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the robustness of published data (Table 1). A literature search
returned 171 relevant peer-reviewed articles published up to
and including 31 January 2006. Of these published articles,
forty-four contained duplicate information. The remaining
publications (n 127) were assessed against the twenty data
quality criteria and those scoring 13/20 or more were
deemed of suitable quality for database inclusion. Information
from ninety-seven papers was entered into the Dietplan6
nutrient database for each PE relevant to the present study.
Data presented in the glucoside form were converted to agly-
cone equivalents. Multiple analytical results (e.g. soya milk)
were averaged for inclusion. Of the 519 individual foods
identified, 312 had existing McCance and Widdowson
codes(32) that corresponded to coding used within Dietplan6;
the remainder were issued with unique PE study codes.
For common composite foods for which the PE content of
individual ingredients was available, ingredient analysis of
standard recipes was used to provide an overall PE content
estimate. Foods were identified, however, that had no pub-
lished PE data. In these instances, additional foods were
analysed by LC–MS/MS (n 34; Table 2), by an established
and well-validated method(16–18) scoring 20/20 in the quality
criteria. These primary analysis data were then entered into
the database.
Chemical analyses
Analysis of urine for PE and metabolites was conducted
by LC–MS/MS(33) (Table 3). An internal standard mix (40ml)
and acetate buffer (175ml) were combined and urine
(500ml) was added, followed by b-glucuronidase solution
(10ml). Mixtures were incubated overnight at 378C and cen-
trifuged before LC–MS/MS analysis of the hydrolysate on a
Waters Ultima triple quadrupole mass spectrometer (Waters
Corporation). Duplicate transitions were measured in negative
electrospray ionisation mode for detection and confirmation
of sixteen PE and their metabolites: genistein; dihydro-
genistein; 6-hydroxy-O-desmethylangolensin; daidzein (Daid);
dihydrodaidzein; equol (Equ); O-desmethyl angolensin;
8-hydroxydaidzein; 3-hydroxydaidzein; glycitein; desmethyl-
glycitein; biochanin A; formononetin; coumestrol; entero-
lactone; enterodiol. The limit of detection was 10mg/l of
urine (about 40 nmol/l). PE metabolites were obtained from
Plantech (Plantech) and 13C-labelled internal standards were
supplied by Dr N. Botting (University of St Andrews)(16,33).
Statistics
Descriptive statistics were used to describe subject character-
istics and PE intakes. Spearman’s rank correlations and
Table 2. Phyto-oestrogen content in new foods
No. mg/kg as consumed Genistein Daidzein Glycitein Biochanin A Formononetin Coumestrol Secoisolariciresinol Matairesinol
1 Black currants ,0·02 ,0·02 ,0·02 0·068 ,0·02 ,0·02 ,0·3 ,0·2
2 Ciabatta ,0·07 ,0·07 ,0·07 ,0·07 ,0·07 ,0·07 ,1 ,0·7
3 Couscous ,0·09 ,0·09 ,0·09 ,0·09 ,0·09 ,0·09 ,2 ,0·9
4 Butter croissant ,0·08 ,0·08 ,0·08 ,0·08 ,0·08 ,0·08 ,2 ,0·8
5 Crumpet ,0·05 ,0·05 ,0·05 ,0·05 ,0·05 ,0·05 ,1 ,0·5
6 Fruit cake ,0·09 ,0·09 ,0·09 ,0·09 ,0·09 ,0·09 6 ,0·9
7 Ginger cake ,0·08 ,0·08 ,0·08 ,0·08 ,0·08 ,0·08 ,2 ,0·8
8 Ginger nut biscuits ,0·5 ,0·5 ,0·5 ,0·1 ,0·1 ,0·1 ,0·5 ,1
9 Ginger root 0·3 0·1 0·1 ,0·01 ,0·01 ,0·01 24 ,0·1
10 Sesame mochi ,0·07 ,0·07 0·3 ,0·07 ,0·07 ,0·07 ,1 ,0·7
11 Black rice mochi ,0·07 ,0·07 ,0·07 ,0·07 ,0·07 0·3 ,1 ,0·7
12 Soreen cake ,0·08 ,0·08 ,0·08 ,0·08 ,0·08 ,0·08 ,2 ,0·8
13 Mange tout steamed 0·01 0·01 7 0·01 0·1 ,0·01 ,0·3 ,0·1
14 Mange tout raw 0·05 0·02 10 0·01 0·1 ,0·01 ,0·2 ,0·1
15 Victorian chutney ,0·1 ,0·1 0·9 ,0·1 ,0·1 0·2 3 ,1
16 Marmite ,0·1 ,0·1 ,0·1 ,0·1 ,0·1 ,0·1 ,2 ,1
17 Marzipan ,0·09 ,0·09 ,0·09 ,0·09 ,0·09 ,0·09 ,2 ,0·9
18 Millet ,0·09 ,0·09 ,0·09 ,0·09 ,0·09 ,0·09 ,1 ,0·9
19 Mini naan ,0·07 ,0·07 ,0·07 ,0·07 ,0·07 ,0·07 ,1 ,0·7
20 Parsley 0·3 ,0·01 ,0·01 ,0·01 ,0·01 ,0·01 0·7 ,0·1
21 Pine nuts ,0·1 ,0·1 ,0·1 ,0·1 ,0·1 ,0·1 ,2 ,1
22 Pumpkin seeds ,0·1 ,0·1 ,0·1 ,0·1 ,0·1 ,0·1 ,2 ,1
23 Quorn fried ,0·04 ,0·04 ,0·04 ,0·04 ,0·04 ,0·04 ,0·7 ,0·3
24 Quorn raw ,0·03 ,0·03 ,0·03 ,0·03 ,0·03 ,0·03 ,0·5 ,0·3
25 Sesame oil ,0·1 ,0·1 ,0·1 ,0·1 ,0·1 ,0·1 ,0·2 ,1
26 Burgen soya bread 149 84 26 ,0·07 ,0·07 ,0·07 ,1 ,0·7
27 Sushi ,0·04 0·2 0·3 ,0·04 ,0·04 ,0·04 1 ,0·4
28 Vegetable sausage cooked 35 27 14 3 0·05 ,0·05 0·9 ,0·5
29 Vegetable sausage raw 27 22 11 3 0·04 ,0·04 0·8 ,0·4
30 Wheatgerm mg/l in
beverages
as consumed
,0·09 ,0·09 ,0·09 ,0·09 ,0·09 0·2 0·2 ,0·9
31 Green tea 0·013 ,0·01 ,0·01 ,0·01 ,0·01 ,0·01 0·45 0·05
32 Cappuccino ,0·01 ,0·01 ,0·01 ,0·01 ,0·01 ,0·01 ,0·01 ,0·01
33 Dandelion coffee ,0·01 ,0·01 ,0·01 ,0·01 ,0·01 ,0·01 ,0·01 ,0·01
34 Horlicks ,0·01 ,0·01 ,0·01 ,0·01 ,0·01 ,0·01 ,0·01 ,0·01
Phyto-oestrogen dietary analysis database 3
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Table 3. Urinary phyto-oestrogen (PE) excretion (mg/d)*
Individual PE and metabolites (mg/d)
PE
Volume
(litres) PABA†
Gen and metab-
olite Daid and metabolites
Gly and metab-
olite
Total PE
(mg/d)No.
intake from food
(mg/d) Gen DHG Daid DHD 3OH-D Equ ODMA Gly DmGly Form End Enl
1 15 162·4 2·82 103 ,LOD‡ ,LOD 90 ,LOD 59 ,LOD 31 ,LOD 203 ,LOD 68 1700 2151
2 14 184·6 2·60 94 ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD 52 ,LOD ,LOD 486 538
3 21 756·6 1·97 88 ,LOD ,LOD 92 ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD 324 416
4 12 428·9 1·42 94 33 30 ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD 112 1088 1263
5 22 101·7 1·48 95 32 ,LOD 61 ,LOD ,LOD 18 24 ,LOD ,LOD ,LOD 56 1116 1307
6 16 835·2 2·71 97 ,LOD ,LOD 371 ,LOD ,LOD 27 ,LOD ,LOD ,LOD 27 87 3339 3851
7 36 857·9 2·17 96 ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD 59 1758 1817
8 3738·2 1·26 83 ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD 40 ,LOD 40
9 4547·1 2·67 98 ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD 77 77
10 8086·4 1·46 98 ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD
11 12 345·0 2·39 92 36 ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD 36
12 13 929·8 1·68 90 23 ,LOD 463 ,LOD ,LOD ,LOD 40 ,LOD ,LOD 18 275 2304 3123
13 8343·2 2·63 102 ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD 203 2768 2971
14 12 597·3 2·38 94 ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD 274 2030 2304
15 21 428·8 3·17 109 ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD 95 95
16 7363·7 2·85 96 ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD
17 49 083·4 2·95 93 1991 121 7779 1027 56 41 1159 693 ,LOD ,LOD ,LOD ,LOD 12 867
18 5115·6 2·60 102 ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD 333 458 791
19 71 971·0 1·84 106 ,LOD 59 ,LOD 322 ,LOD ,LOD 103 ,LOD ,LOD ,LOD 3365 9754 13 603
20 1944·2 2·80 104 ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD 532 532
21 10 141·1 1·95 93 5345 123 5850 289 ,LOD 1361 177 396 ,LOD ,LOD ,LOD 1244 14 785
22 33 575·6 3·14 81 3458 342 3141 1135 31 ,LOD 339 ,LOD ,LOD ,LOD 91 ,LOD 8537
23 17 053·0 1·50 92 ,LOD ,LOD 260 ,LOD ,LOD ,LOD 53 ,LOD ,LOD ,LOD 44 293 650
24 13 595·2 2·25 109 ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD 259 ,LOD 259
25 49 094·0 1·50 112 2672 365 2231 822 ,LOD ,LOD 95 18 ,LOD ,LOD 135 2190 8528
26 27 534·9 2·70 97 ,LOD ,LOD ,LOD 103 ,LOD 27 ,LOD ,LOD 57 ,LOD ,LOD 378 565
27 22 339·8 3·75 89 ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD
28 15 017·1 2·90 103 249 ,LOD 818 ,LOD ,LOD ,LOD 128 ,LOD ,LOD ,LOD ,LOD 452 1647
29 17 148·7 3·10 107 143 ,LOD 78 ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD 221
30 8320·1 2·71 95 ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LO,D ,LOD 73 1463 1536
31 44 739·7 2·50 99 7555 178 6328 335 48 ,LOD 258 50 ,LOD ,LOD ,LOD 80 14 832
32 760·1 2·49 80 ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD 35 1467 1502
33 13 833·8 1·56 100 555 225 1097 448 ,LOD ,LOD 37 87 ,LOD ,LOD ,LOD 1296 3745
34 10 410·8 2·04 91 ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD
35 1195·8 1·89 80 289 ,LOD 818 ,LOD ,LOD ,LOD 43 38 ,LOD ,LOD 53 584 1825
36 6907·6 6·16 94 ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD 942 942
37 37 792·0 2·83 79 34 ,LOD 464 ,LOD ,LOD 42 45 ,LOD ,LOD ,LOD 382 6523 7490
38 7192·4 3·15 99 ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD ,LOD 491 491
Mean 18 328·2 2·472 96 590 38 788 118 5 40 67 34 8 1 156 1190 3035
SD 15 617·5 0·866 8 1610 92 1869 285 16 220 197 128 35 5 545 1914 6916
Gen, genistein; Daid, daidzein; Gly, glycitein; PABA, para-aminobenzoic acid; DHG, dihydrogenistein; DHD, dihydrodaidzein; 3OH-D, 3-hydroxydaidzein; Equ, equol; ODMA, O-desmethyl angolensin; DMGly, desmethylglycitein;
Form, formononetin; End, enterodiol; Enl, enterolactone; LOD, limit of detection.
* No coumestrol, biochanin A, 6-hydroxy-O-desmethylangolensin or 8-hydroxydaidzein was detected in any urine sample.
† Percentage recovery of 3 £ 80 mg of PABA.
‡ Less than 10mg/l
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Bland–Altman plots were used to assess the relationship
between estimated PE intakes using the 4 d diaries and urinary
PE excretion results(34). Statistical analyses were conducted
using SPSS (version 12, annex 6; SPSS, Inc.).
Results
The dietary analysis database created in the present study
used a more critical evaluation of the published literature
than has been the case for previous databases(26) and com-
plies with the guidance on reporting clinical studies of soya
intervention(35). The present study further benefited from the
inclusion of the primary analysis of an additional thirty-four
food and beverage items known to be consumed by the
study population and for which PE content data were lacking.
Considerable recoding of the food and beverage items listed
in the diaries was required to allow the PE study data to
be read alongside the macronutrient assessment data within
each report from 551 separately coded foods (see the
Supplementary material, available online). The process of
recoding the food items was also indicated when the actual
food or beverage was not explicitly listed within the database,
but was deemed dietetically similar. For example, PE fraction
data were available for fresh tomatoes. Giving due consider-
ation to the fact that food processing and cooking generally
reduce the PE content, through loss of water (dehydration)
or boiling (aqueous extraction)(36), tinned tomatoes and
grilled tomatoes were recoded accordingly, so as to represent
their potential contribution to the intake of the respective
PE fractions.
Recovery of 85–110 % of the PABA dose from the urine is
generally accepted as complete urine collection. Values of
less than 70 % indicate incomplete urine collection(37). There
was a trend (P,0·1) for the older women in the present
study to excrete slightly less PABA in the 24 h urine collection.
This is consistent with the literature, although the reduction
in excretion is only small(38). Taking this into account, the
cut-off was revised to 100 ^ 22 % recovery of the PABA
dose; thirty-eight of the fifty-four urine collections were thus
deemed adequate, with an average recovery of 95 (SD 8) %.
The urinalysis results are shown in Table 3. Biochanin A,
8-hydroxydaidzein and coumestrol were not detected in
any samples and have, therefore, been excluded from the
data table. The mean total PE excretion was 3·0 (SD 6·9)mg/d
(n 38, ,0·01–15 mg/d)
Of the fifty-four women (15 %) who provided a 24 h urine
collection, eight were found to be Equ producers, based on
the detection of more than 10mg/l (41·3 nmol/l) of Equ. Of
these eight women, two (4 %) excreted Equ at levels greater
than 1000 nmol/d (4198 and 5618 nmol Equ/d) and could be
described as good Equ producers on this basis. The remaining
six excreted 74–173 nmol Equ/d and were, therefore, poor
Equ producers. Of the six Equ producers, five provided com-
plete urine samples, as confirmed by PABA analysis, hence
one of the high Equ producers was excluded from subsequent
analysis. Setchell & Cole(39) has designated a formula based on
a nmol/l urinary log10 Equ:Daid ratio of .21·75 as indicating
Equ production, with expected distributions of 25 % in
non-vegetarian adults and 59 % in vegetarian adults after a
Daid challenge. This is a more intuitive approach that can
better predict which subjects would be high Equ excreters
given a suitable Daid challenge. Of the fifty-four subjects,
twenty-two had detectable urinary Daid or Equ levels; it was
necessary to enter a non-zero value (0·05mg/l) in place of
, limit of detection (10mg/l) in order to use the formula.
It can clearly be seen that seven (15 %) of the fifty-four were
then classified as Equ producers (Fig. 1). As many subjects
had excreted neither Equ nor Daid, this dataset only supports
the hypothesis that 25 % of subjects are Equ producers in
contrast to those (seven (32 %) out of twenty-two) whose
urine contained isoflavones.
The Spearman’s correlation coefficients measured in the
present study (Tables 4 and 5) are virtually identical to the
best recent examples(19), with recent diet to urine values of
0·54 (isoflavones and total PE) and 0·40 (lignans) and urinary
to FFQ correlations for total isoflavones (Daid, genistein and
Equ) of 0·57 (95 % CI), increasing to 0·72 for the 24 h recall(40).
Literature correlations reflecting the reproducibility of the FFQ
of 0·67–0·81 and validity correlations (FFQ compared with
dietary) of 0·67–0·79 with urinary validity correlations of
0·41–0·51 (isoflavones) and 0·16–0·21 (lignans) are reported(25)
Discussion
The volume of collected urine was 2·52 (SD 0·88) litres (n 54,
1·26–6·16 litres) and, while this was considerably higher than
volumes measured in similar studies, it was largely unchanged
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Fig. 1. Comparison of equol production status by (a) concentration and (b)
log10 transformation of the metabolite:precursor ratios. , Daidzein; , equol.
(A colour version of this figure can be found online at http://www.journals.
cambridge.org/bjn).
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by the elimination of the incomplete collections (2·47 (SD 0·87)
litres; n 38, 1·26–6·16 litres). This indicates that low collection
volume was not the major factor in the low completion rate.
The urinalysis results and 7 d weighed intakes contributed
to the validation of the 4 d food and drink diary as a
data collection tool. Variations between subjects in terms
of absorption, distribution, metabolism and excretion of PE
fractions and their excretion products are an important con-
sideration when interpreting PE urinalysis results overall.
While an attempt to control for such inter-individual variations
could be made by comparing averaged dietary intake over
4 d with the urinalysis results, it would not be possible to
individually predict the rate at which PE fractions and
their excretion products would appear in urine. This may
warrant attempts to collect urine over a longer period in
future studies.
Data on PE intake in other study populations have been
reported in the literature(4,41–47). A direct comparison of quan-
tified intakes is difficult as some researchers have reported
intakes of a limited number of individual PE and the dietary
analysis database used to quantify intake is not always explicit.
There is considerable methodological variation between these
studies. In particular, the derivation of the dietary analysis
database used in each study is not always clear. Given that
such variation introduces error, a quantitative comparison
between study populations is difficult to achieve. While it
is beyond the scope of the present study to conduct any stat-
istical comparisons between the study populations described
by other researchers and the present results, a review of the
published data does reinforce the need to ensure that a com-
prehensive and quality-assured dietary analysis database is
used in such studies. The need to comprehensively analyse
foodstuffs for more than just their isoflavone PE content is
also evident. In general, the British are low consumers of
soya(48) and the contribution of low-isoflavone foodstuffs
is potentially under-represented in existing dietary analysis
databases.
Thus, assessing intake and exposure should consider other
PE fraction sources with known biological activity. A high
intake of dietary lignans, for example, has been associated
with a reduced risk of breast cancer in a large cohort study
of French women, a population that does not consume a
diet rich in soya products(49). The techniques for quantifying
lignan intake are not comprehensively described and the qual-
ity of the database used to analyse intake warrants review.
However, these findings suggest an emerging role for dietary
lignans with respect to breast cancer.
The interpretation of correlations with the urinalysis results
is complicated by the known inter-individual variations in the
enterohepatic circulation and the efficiency of microbial con-
version of PE into other bioactive oestrogenic metabolites in
the gut. Identifying ‘equol producers’ is important, however,
in the assessment of exposure to PE, particularly in a poten-
tially hyper-exposed subgroup of the population such as
women who have been treated for breast cancer.
Conclusion
The present study provide a unique opportunity to create a
bespoke dietary analysis database to measure PE consump-
tion. It was informed by the dietary consumption patterns of
women who had previously been treated for postmenopausal
breast cancer and who were, as such, potential high consu-
mers of PE compared with the general population. Quantify-
ing true dietary intake is always challenging as the very
attempts to measure it can alter actual and reported consump-
tion. However, when validated methods for recording dietary
intake are used, the methods to quantify intake rely upon a
comprehensive nutrient database so that consumption can
be meaningfully assessed.
Women who have been treated for breast cancer are likely
to have different PE intakes which reflect differences in indi-
vidual food preferences and, quite possibly, variations in the
women’s existing knowledge of PE themselves. The avail-
ability of a comprehensive database for reliably measuring
PE intake is a valuable resource for researchers and healthcare
professionals who wish to measure intake and discuss in detail
the contribution of these bioactive compounds to the health
of the population.
Table 4. Spearman’s correlations between phyto-oestrogen (PE)
intake (mg/1000 kcal/d) measured using 4 d diaries and 7 d weighed
intake data
Dietary PE Spearman’s r
Daidzein 0·723**
Genistein 0·763**
Glycitein 0·714**
Formononetin 20·070
Biochanin A 0·225
Coumesterol 0·563*
Matairesinol 0·622*
Secoisolariciresinol 0·640*
Total PE 0·749**
*P,0·05 **P,0·1.
Table 5. Spearman’s correlations between estimated dietary and
measured urinary phyto-oestrogen (PE) values
Dietary PE
(mg/d)
Urinary PE and
metabolite (mg/l) Spearman’s r
Daidzein Daidzein 0·517**
Daidzein Dihydrodaidzein 0·398**
Daidzein 3-Hydroxydaidzein 0·403**
Daidzein O-DMA 0·534**
Daidzein 6-OH-O-DMA 0·267
Daidzein Equol 20·147
Daidzein Daidzein and metabolites† 0·492**
Genistein Genistein 0·507**
Genistein Dihydrogenistein 0·468**
Glycitein Glycitein 0·441**
Glycitein Desmethylglycitein 20·021
Matairesinol Enterodiol 0·079
Matairesinol Enterolactone 0·088
Secoisolariciresinol Enterodiol 0·287
Secoisolariciresinol Enterolactone 0·221
Matairesinol þ
secoisolariciresinol
Enterodiol þ
enterolactone
0·238
Total PE Total phyto-oestrogens 0·450**
**P,0·1.
† Daidzein and metabolites ¼ daidzein, dihydrodaidzein, 3-hydroxydaidzein,
O-desmethylangolensin (O-DMA) and 6-hydroxy-O-DMA.
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